Bullous DRESS in a patient on strontium ranelate

Clinical and Experimental Dermatology

Volumn 34, Issue 7, 2009, Pages

  Kramkimel, N ^a   Sibon, C ^a   Le Beller, C ^b   Saiag, P ^a   Mahe E ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; STRONTIUM RANELATE;

AGED; ANAMNESIS; BLISTER; CASE REPORT; CLINICAL FEATURE; DRESS SYNDROME; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LETTER; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

AGED; BONE DENSITY CONSERVATION AGENTS; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; HUMANS; ORGANOMETALLIC COMPOUNDS; SKIN DISEASES, VESICULOBULLOUS; THIOPHENES;

EID: 70349489115     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03302.x     Document Type: Letter

References (4)

1. O'Donnell S, Cranney A, Wells GA et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006 (4) : CD005326.
2. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 350 : 459 468. (Pubitemid 38133766)
3. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005 209 : 123 129.
4. European Medicines Agency. EMEA Recommends Changes in the Product Information for Protelos/Osseor Due to the Risk of Severe Hypersensitivity Reactions. 2007, http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/ PressRelease-Protelos-41745807en.pdf.